Get the Stockscreener App
85.69
0.28%
0.24
After Hours:
85.69
Nuvalent Inc stock is traded at $85.69, with a volume of 474.18K.
It is up +0.28% in the last 24 hours and up +12.66% over the past month.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
See More
Previous Close:
$85.45
Open:
$85.44
24h Volume:
474.18K
Relative Volume:
0.87
Market Cap:
$5.69B
Revenue:
-
Net Income/Loss:
$-224.29M
P/E Ratio:
-21.97
EPS:
-3.9
Net Cash Flow:
$-185.06M
1W Performance:
+4.41%
1M Performance:
+12.66%
6M Performance:
+12.99%
1Y Performance:
+6.45%
1-Day Range:
$84.98
$86.83
1-Week Range:
$80.02
$86.83
52-Week Range:
$55.53
$113.51
Nuvalent Inc Stock (NUVL) Company Profile
Name
Nuvalent Inc
Sector
Industry
Phone
508-446-2272
Address
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
85.69 | 5.89B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-14-25 | Upgrade | UBS | Neutral → Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Oct-24-24 | Initiated | UBS | Neutral |
| Aug-29-24 | Initiated | Barclays | Overweight |
| Apr-17-24 | Initiated | Jefferies | Buy |
| Apr-01-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-28-24 | Resumed | Guggenheim | Buy |
| Feb-23-24 | Initiated | Robert W. Baird | Outperform |
| Sep-27-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-24-23 | Initiated | Guggenheim | Buy |
| Jan-18-23 | Initiated | Wedbush | Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
View All
Nuvalent Inc Stock (NUVL) Latest News
Nuvalent(NUVL) Shares Soar 3.01% on Positive Clinical Data - AInvest
Nuvalent, Inc. (NASDAQ:NUVL) Stock Position Decreased by Teacher Retirement System of Texas - Defense World
Why Nuvalent Inc. stock attracts strong analyst attentionDaily Trade Opportunity - Newser
How Nuvalent Inc. stock performs during market volatilityFree Capital Allocation Plans - Newser
What makes Nuvalent Inc. stock price move sharplyFree Access to Stock Community - Newser
Recent Analysts’ Ratings Updates for Nuvalent (NUVL) - Defense World
Insider Selling: Nuvalent, Inc. (NASDAQ:NUVL) Insider Sells $439,890.00 in Stock - Defense World
Nuvalent's Insider Sales and Clinical Milestones: A Balancing Act for Investors - AInvest
Nuvalent(NUVL) Shares Soar 3.47% on Positive Lung Cancer Data - AInvest
Nuvalent’s SWOT analysis: biotech stock’s pivotal year ahead By Investing.com - Investing.com Nigeria
Nuvalent’s SWOT analysis: biotech stock’s pivotal year ahead - Investing.com
Nuvalent Announces Positive Pivotal Data for Zidesamtinib in Lung Cancer - Insider Monkey
10 Best High Short Interest Stocks With Huge Upside Potential - Insider Monkey
Nuvalent (NUVL) Gets a Buy from Goldman Sachs - The Globe and Mail
Nuvalent (NASDAQ:NUVL) Upgraded at The Goldman Sachs Group - Defense World
Goldman Sachs initiates coverage on Nuvalent stock with Buy rating By Investing.com - Investing.com India
Nuvalent chief development officer Noci sells $314k in shares - Investing.com
Barclays Sticks to Its Buy Rating for Nuvalent (NUVL) - The Globe and Mail
Nuvalent Believes Safety Profile Can Help Zidesamtinib Be ROS-1 Lung Cancer Leader - insights.citeline.com
Nuvalent stock price target raised to $114 from $100 at UBS - Investing.com
Transcript : Nuvalent, Inc.Special Call - MarketScreener
Nuvalent Reports Positive Pivotal Data From ARROS-1 Study Of Zidesamtinib - Nasdaq
Breakthrough Data Coming: Nuvalent's ROS1 Inhibitor Results in Treatment-Resistant Lung Cancer - Stock Titan
Nuvalent Appoints Christy Oliger to Board of Directors - The Malaysian Reserve
Nuvalent appoints former Genentech oncology executive to board - Investing.com
Nuvalent appoints Christy Oliger to board of directors - MarketScreener
Nuvalent Adds Former Genentech Oncology SVP to Board Ahead of 2026 Launch Plans | NUVL Stock News - Stock Titan
Nuvalent’s SWOT analysis: biotech stock poised for pivotal year in NSCLC treatment - Investing.com
GAMMA Investing LLC Boosts Stake in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
(NUVL) Long Term Investment Analysis - news.stocktradersdaily.com
Rhumbline Advisers Acquires 2,572 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent’s SWOT analysis: brain-penetrant TKIs poised to reshape NSCLC stock By Investing.com - Investing.com South Africa
Nuvalent’s SWOT analysis: brain-penetrant TKIs poised to reshape NSCLC stock - Investing.com India
Nuvalent Inc. Maintains Momentum Amid Leadership Shift: A Strong Buy on Upcoming Catalysts - AInvest
Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results - Seeking Alpha
Nuvalent board member Emily Conley resigns By Investing.com - Investing.com Nigeria
Nuvalent board member Emily Conley resigns - Investing.com
Nuvalent Board Member Emily Conley Resigns - TipRanks
How the (NUVL) price action is used to our Advantage - news.stocktradersdaily.com
Nuvalent, Inc. Reports Q1 2025 Financial Results - TipRanks
Nuveen Asset Management LLC Has $6.62 Million Stock Position in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium - The Globe and Mail
Nuvalent (NUVL) Stock on the Rise: Decoding the 4.7% Surge and Price Potential - Daily Chhattisgarh News
Nuvalent’s SWOT analysis: cancer drug developer’s stock faces pivotal year By Investing.com - Investing.com Nigeria
Nuvalent’s SWOT analysis: cancer drug developer’s stock faces pivotal year - Investing.com Australia
Deutsche Bank AG Has $2.79 Million Stock Holdings in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent, Inc. (NASDAQ:NUVL) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Nuvalent, Inc. (NASDAQ:NUVL) Shares Acquired by Bank of America Corp DE - Defense World
BNP Paribas Financial Markets Acquires Shares of 17,366 Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent, Inc. (NASDAQ:NUVL) Shares Sold by Dimensional Fund Advisors LP - Defense World
A Bullish 2025 Outlook For Nuvalent Inc (NASDAQ: NUVL) Shares - Stocksregister
Nuvalent Inc Stock (NUVL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):